This application seeks continued support to replace and to extend the existing Medication Development Unit for Stimulant Abuse (P50 DA 12755). The thematic emphasis that unifies this continuation of the Center is the development of pharmacological treatments for stimulant abuse through comprehensive and efficient methodologies applied by a multidisciplinary team. The P50 project activities aligned with this theme will involve an ever greater linkage of Phase I with Phase II work, an even stronger effort to apply advanced biostatistical methods to isolate effects of missing data and to identify potential medication effects in subgroups, a more concerted effort to develop biomarkers that discriminate meaningful differences in outcomes, and a more focused approach to the evaluation of medications within the context of carefully specified and timed behavioral interventions. This P50 Center continuation proposes a Core for conducting Administrative and Scientific Integration and Phase I and Phase II research projects that will complete the development of four medications for methamphetamine abuse from initial stages of safety/interaction through preliminary efficacy trials.
The Specific Aims of this coordinated research activity are: (1) to identify and test novel medications for the treatment of stimulant abuse and dependence; (2) to conduct Phase I and Phase II trials of approved medications and novel compounds with potential for the treatment of stimulant-related disorders, in the context of concurrent behavioral treatments; and (3) to improve the efficiency of conducting medications research by using best practices and by applying cutting-edge biostatistical methods when analyzing trials data, creating a resource available to the field as a center of excellence in the area of clinical trials for stimulant abuse and dependence. The activities of the Core and two research projects in this application are designed to reflect innovation and multidisciplinary effort to maximize the likelihood of finding breakthroughs in the pharmacological treatment of stimulant abuse that can be brought into practice.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Specialized Center (P50)
Project #
1P50DA018185-01
Application #
6813383
Study Section
Special Emphasis Panel (ZDA1-KXA-N (22))
Program Officer
Montoya, Ivan
Project Start
2004-09-29
Project End
2009-07-31
Budget Start
2004-09-29
Budget End
2005-07-31
Support Year
1
Fiscal Year
2004
Total Cost
$1,181,023
Indirect Cost
Name
University of California Los Angeles
Department
Psychiatry
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Cook, Ryan; Quinn, Brendan; Heinzerling, Keith et al. (2017) Dropout in clinical trials of pharmacological treatment for methamphetamine dependence: the role of initial abstinence. Addiction 112:1077-1085
Mahoney 3rd, James J; De La Garza 2nd, Richard; Jackson, Brian J et al. (2014) The relationship between sleep and drug use characteristics in participants with cocaine or methamphetamine use disorders. Psychiatry Res 219:367-71
Verrico, Christopher D; Haile, Colin N; Newton, Thomas F et al. (2013) Pharmacotherapeutics for substance-use disorders: a focus on dopaminergic medications. Expert Opin Investig Drugs 22:1549-68
Brensilver, Matthew; Heinzerling, Keith G; Shoptaw, Steven (2013) Pharmacotherapy of amphetamine-type stimulant dependence: an update. Drug Alcohol Rev 32:449-60
Brensilver, Matthew; Heinzerling, Keith G; Swanson, Aimee-Noelle et al. (2013) Cigarette smoking as a target for potentiating outcomes for methamphetamine abuse treatment. Drug Alcohol Rev 32:96-9
Heinzerling, Keith G; Shoptaw, Steven (2012) Gender, brain-derived neurotrophic factor Val66Met, and frequency of methamphetamine use. Gend Med 9:112-20
Brensilver, Matthew; Tariq, Shabana; Shoptaw, Steven (2012) Optimizing pain management through collaborations with behavioral and addiction medicine in primary care. Prim Care 39:661-9
Mahoney, James J; Jackson, Brian J; Kalechstein, Ari D et al. (2012) Acute modafinil exposure reduces daytime sleepiness in abstinent methamphetamine-dependent volunteers. Int J Neuropsychopharmacol 15:1241-9
Brensilver, Matthew; Heinzerling, Keith G; Swanson, Aimee-Noelle et al. (2012) A retrospective analysis of two randomized trials of bupropion for methamphetamine dependence: suggested guidelines for treatment discontinuation/augmentation. Drug Alcohol Depend 125:169-72
Brensilver, Matthew; Heinzerling, Keith G; Swanson, Aimee-Noelle et al. (2012) Placebo-group responders in methamphetamine pharmacotherapy trials: the role of immediate establishment of abstinence. Exp Clin Psychopharmacol 20:430-5

Showing the most recent 10 out of 32 publications